2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.20 EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma

EP.12A.20 EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma

Back to course

Pdf Summary

The study examines the effectiveness of combining epidermal growth factor receptor (EGFR) inhibitors with intrathoracic perfusion chemotherapy in managing malignant pleural effusion (MPE) in patients with EGFR-mutated metastatic lung adenocarcinoma. MPE is a severe complication associated with metastatic lung cancer, leading to poor prognosis and significant clinical symptoms. EGFR inhibitors are a standard treatment option for specific mutations but have shown variable effectiveness across different metastatic sites.<br /><br />The retrospective study involved 31 patients with a mean age of 52 years, all diagnosed with stage IV lung adenocarcinoma and EGFR mutations, primarily either the 19-del or L858R mutations. Patients were treated with tyrosine kinase inhibitors (TKIs) either alone (monotherapy) or in combination with platinum-based intrathoracic perfusion.<br /><br />The results indicated a significant improvement in outcomes for patients receiving the combined treatment compared to monotherapy. The median overall survival for the combination therapy was 45 months, substantially longer than the 19 months for monotherapy. This suggests that the combined approach is associated with a more favorable prognosis (HR 0.017; 95% CI, 0.04-0.84; P = 0.030).<br /><br />The study encompassed patients from West China Hospital, Sichuan University, who were treated between 2013 and 2019. They underwent next-generation sequencing or real-time PCR to identify gene mutations before receiving the respective treatments.<br /><br />In conclusion, the combination of TKIs with intrathoracic perfusion shows promise in managing disease progression and improving outcomes for stage IV lung adenocarcinoma patients with EGFR mutations. These findings might guide future treatment protocols and emphasize the need for further studies on efficacy, safety, and patient comfort.

Asset Subtitle

Weijia Huang

Meta Tag

Speaker Weijia Huang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR inhibitors

intrathoracic perfusion chemotherapy

malignant pleural effusion

metastatic lung adenocarcinoma

tyrosine kinase inhibitors

platinum-based therapy

overall survival

next-generation sequencing

gene mutations

West China Hospital